Abstract
BALB/c mice are predisposed to developing spontaneous mammary tumors, which are further increased in a p53 heterozygous state. C57BL/6J mice are resistant to induced mammary tumors and develop less than 1% mammary tumors in both wild-type and p53 +/− states. To map modifiers of mammary tumorigenesis, we have established F1 and F2 crosses and backcrosses to BALB/cJ (N2-BALB/cJ) and C57BL/6J (N2-C57BL/6J) strains. All cohorts developed mammary carcinomas in p53 +/− females, suggesting that multiple loci dominantly and recessively contributed to mammary tumorigenesis. We mapped two modifiers of mammary tumorigenesis in the BALB/cJ strain. Mtsm1 (mammary tumor susceptibility modifier), a dominant-acting modifier, is located on chromosome 7. Mtsm1 is suggestive for linkage to mammary tumorigenesis (p = 0.001). We have analyzed the Mtsm1 region to locate candidate genes by comparing it to a rat modifier region, Mcs3, which shares syntenic conservation with Mtsm1. Expression data and SNPs were also taken into account. Five potential candidate genes within Mtsm1 are Aldh1a3, Chd2, Nipa2, Pcsk6, and Tubgcp5. The second modifier mapped is Mtsm2, a recessive-acting modifier. Mtsm2 is located on chromosome X and is significantly linked to mammary tumorigenesis (p = 1.03 × 10−7).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Altman PL, Katz DD (1979) Inbred and genetically defined strains of laboratory animals (Bethesda, MD: Federation of American Societies for Experimental Biology)
Balmain A, Gray J, Ponder B (2003) The genetics and genomics of cancer. Nat Genet 33 Suppl:238–244
Blackburn AC, Brown JS, Naber SP, Otis CN, Wood JT, et al. (2003) BALB/c alleles for Prkdc and Cdkn2a interact to modify tumor susceptibility in Trp53+/− mice. Cancer Res 63:2364–2368
Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591–602
Bond GL, Hu W, Levine A (2005) A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 65:5481–5484
Brown BW, Costello TJ, Hwang SJ, Strong LC (2005) Generation or birth cohort effect on cancer risk in Li-Fraumeni syndrome. Hum Genet 118:489–498
Chai JH, Locke DP, Greally JM, Knoll JH, Ohta T, et al. (2003) Identification of four highly conserved genes between breakpoint hotspots BP1 and BP2 of the Prader-Willi/Angelman syndromes deletion region that have undergone evolutionary transposition mediated by flanking duplicons. Am J Hum Genet 73:898–925
Cheng M, Watson PH, Paterson JA, Seidah N, Chretien M, et al. (1997) Pro-protein convertase gene expression in human breast cancer. Int J Cancer 71:966–971
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, et al. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215–221
Donehower LA, Harvey M, Vogel H, McArthur MJ, Montgomery CA Jr, et al. (1995) Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog 14:16–22
Eppig JT, Bult CJ, Kadin JA, Richardson JE, Blake JA, et al. (2005) The Mouse Genome Database (MGD): from genes to mice—a community resource for mouse biology. Nucleic Acids Res 33:D471–D475
Evans SC, Lozano G (1997) The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today 3:390–395
Harvey M, McArthur MJ, Montgomery CA Jr, Bradley A, Donehower LA (1993) Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J 7:938–943
Heston WE, Vlahakis G (1971) Mammary tumors, plaques, and hyperplastic alveolar nodules in various combinations of mouse inbred strains and the different lines of the mammary tumor virus. Int J Cancer 7:141–148
Hwang SJ, Cheng LS, Lozano G, Amos CI, Gu X, et al. (2003) Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 113:238–243
Iwakuma T, Parant JM, Fasulo M, Zwart E, Jacks T, et al. (2004) Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene 23:7644–7650
Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, et al. (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4:1–7
Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H (1997) Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 150:1–13
Kuperwasser C, Hurlbut GD, Kittrell FS, Dickinson ES, Laucirica R, et al. (2000) Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome Am J Pathol 157:2151–2159
Lander E, Kruglyak L (1995) Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 11:241–247
Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238
Mira YLR, Zheng WL, Kuppumbatti YS, Rexer B, Jing Y, et al. (2000) Retinol conversion to retinoic acid is impaired in breast cancer cell lines relative to normal cells. J Cell Physiol 185:302–309
Murphy SM, Preble AM, Patel UK, O’Connell KL, Dias DP, et al. (2001) GCP5 and GCP6: two new members of the human gamma-tubulin complex. Mol Biol Cell 12:3340–3352
Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, et al. (1999) Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 64:1371–1377
Rexer BN, Zheng WL, Ong DE (2001) Retinoic acid biosynthesis by normal human breast epithelium is via aldehyde dehydrogenase 6, absent in MCF-7 cells. Cancer Res 61:7065–7070
Shepel LA, Lan H, Haag JD, Brasic GM, Gheen ME, et al. (1998) Genetic identification of multiple loci that control breast cancer susceptibility in the rat. Genetics 149:289–299
Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH (1990) Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747–749
Trkova M, Hladikova M, Kasal P, Goetz P, Sedlacek Z (2002) Is there anticipation in the age at onset of cancer in families with Li-Fraumeni syndrome? J Hum Genet 47:381–386
Vitezica ZG, Elsen JM, Rupp R, Diaz C (2005) Using genotype probabilities in survival analysis: a scrapie case. Genet Sel Evol 37:403–415
Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK (1998) Cancer incidence and mortality, 1973–1995: a report card for the U.S. Cancer 82:1197–1207
Woodage T, Basrai MA, Baxevanis AD, Hieter P, Collins FS (1997) Characterization of the CHD family of proteins. Proc Natl Acad Sci U S A 94:11472–11477
Acknowledgments
These studies were supported by fellowships from the American Legion Auxiliary and Schissler Family Foundation to JGK, the training grants in Molecular Genetics of Cancer (CA009299) UO1 CA-04-002 and PO1 CA34936 to GL, and the Cancer Center Support Grant (CA16672) to M. D. Anderson Cancer Center.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Koch, J.G., Gu, X., Han, Y. et al. Mammary tumor modifiers in BALB/cJ mice heterozygous for p53 . Mamm Genome 18, 300–309 (2007). https://doi.org/10.1007/s00335-007-9028-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00335-007-9028-2